Study of XL999 in Patients With Acute Myeloid Leukemia (AML)
Status:
Terminated
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
This clinical study is being conducted at multiple sites to determine the activity, safety
and tolerability of XL999 when given weekly to patients with relapsed or newly-diagnosed AML.
XL999 is a small molecule inhibitor against Flk1/kinase insert domain receptor (KDR), PDGFR,
c-Kit, FLT3 and SRC. c-Kit and FLT3 are receptors commonly expressed on AML blasts.